SPH 3127

Drug Profile

SPH 3127

Alternative Names: SPH3127

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation; Shanghai Pharmaceuticals Holding
  • Developer Shanghai Pharmaceuticals Holding
  • Class Antihypertensives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hypertension

Most Recent Events

  • 23 Oct 2017 Shanghai Pharmaceuticals initiates enrolment in a phase I trial for Hypertension (In volunteers) in China (PO) (NCT03255993)
  • 23 Sep 2017 Shanghai Pharmaceuticals initiates enrolment in a phase I trial for Hypertension (In volunteers) in China (PO) (NCT03249753)
  • 23 Aug 2017 Shanghai Pharmaceuticals plans a phase I trial for Hypertension (In volunteers) (NCT03255993)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top